KEGG   DRUG: Marstacimab
Entry
D11261                      Drug                                   
Name
Marstacimab (USAN);
Marstacimab (genetical recombination) (JAN);
Marstacimab-hncq;
Hympavzi (TN)
Product
Formula
C6304H9766N1678O2006S44
Exact mass
142480.1473
Mol weight
142567.98
Sequence
(Heavy chain)
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA ISGSGGSTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAILG ATSLSAFDIW GQGTMVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPEAAGA
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPG
(Light chain)
QSVLTQPPSV SGAPGQRVTI SCTGSSSNIG AGYDVHWYQQ LPGTAPKLLI YGNSNRPSGV
PDRFSGSKSG TSASLAITGL QAEDEADYYC QSYDSSLSGS GVFGGGTKLT VLGQPKAAPS
VTLFPPSSEE LQANKATLVC LISDFYPGAV TVAWKADSSP VKAGVETTTP SKQSNNKYAA
SSYLSLTPEQ WKSHRSYSCQ VTHEGSTVEK TVAPTECS
(Disulfide bridge: H22-H96, H147-H203, H223-L217, H229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'147-H'203, H'223-L'217, H'264-H'324, H'370-H'428, L22-L90, L140-L199, L'22-L'90, L'140-L'199)
  Type
Peptide
Remark
Therapeutic category: 6349
ATC code: B02BX11
Product: D11261<JP/US>
Efficacy
Bleeding suppressant, Anti-tissue factor pathway inhibitor antibody
  Disease
Hemophilia A [DS:H00219]
Hemophilia B [DS:H00219]
  Type
Monoclonal antibody
Comment
Preventing bleeding in patients with hemophilia
Target
TFPI [HSA:7035] [KO:K03909]
  Pathway
hsa04610  Complement and coagulation cascades
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B02 ANTIHEMORRHAGICS
   B02B VITAMIN K AND OTHER HEMOSTATICS
    B02BX Other systemic hemostatics
     B02BX11 Marstacimab
      D11261  Marstacimab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Blood Products and Modifiers
  Blood Component Deficiency/ Replacement
   Blood Component Deficiency/ Replacement, Hemophilia A
    Marstacimab
     D11261  Marstacimab (USAN)
   Blood Component Deficiency/ Replacement, Hemophilia B
    Marstacimab
     D11261  Marstacimab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   634  Human blood preparations
    6349  Others
     D11261  Marstacimab (USAN); Marstacimab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Peptidases and inhibitors
  Peptidase inhibitors
   Kunitz/BPTI family
    TFPI
     D11261  Marstacimab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11261
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11261
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11261
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11261
Other DBs
CAS: 1985638-39-8
PubChem: 384585239
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system